Mesoblast [ASX:MSB] Shares Fall 12% On Litigation Update
Biotech stock Mesoblast [ASX:MSB] plunged 12% on Tuesday after updating the market on a second class action lawsuit lodged against it.
ASX:MSB
Mesoblast [ASX:MSB] Shares Fall On Q3 Results
Biotech company Mesoblast [ASX:MSB] released its third quarter results today with MSB shares trading down following the update.
MSB Share Price Up — Trial Drug Helps Against Heart Attacks (ASX:MSB)
Up-and-coming biotech player Mesoblast [ASX:MSB] is on the up today. The regenerative medicine company announced some promising results from a Phase III drug trial from data that was shared at the American Heart Association’s annual ‘Scientific Sessions’, an exhibition of the latest findings and insights into all things heart health related.
Mesoblast Shares Tumble as Losses Widen (ASX:MSB)
The MSB share price down 14%. The Mesoblast [ASX:MSB] posted a FY21 net loss of $98.8 million as the FDA asks for further trials of MSB’s emergency COVID treatment...
Mesoblast Share Price Bounce Back on Positive Trial Data (ASX:MSB)
It seems 2021 continues to be a tough year for the ever-volatile Mesoblast Ltd [ASX:MSB]. Thankfully though, today has brought some relief to shareholders. The MSB share price is up 7.38%...
Mesoblast Share Price Down — Secures a Dire Cash Injection (ASX:MSB)
Seven months ago Mesoblast Ltd [ASX:MSB] was on a tear. This high-flying biotech looked like it had the makings of something great.
Today though, that couldn't be further from the truth. The MSB share price is down 5.08%.
Mesoblast Share Price Crushed as Clinical Trial is Brought to a Halt
The Mesoblast Ltd [ASX:MSB] share price has been absolutely hammered today, trading 32.63% lower at time of writing. The result comes as the company shared some disheartening news. The trial of its remestemcel-L therapy...
Mesoblast Share Price Crashes on Heart Failure Therapy Results
Mesoblast Ltd [ASX:MSB] shares have taken a heavy hit today on the back of phase three chronic heart failure results for its rexlemestrocel-L therapy. The Mesoblast share price has tracked fairly well this year...
Mesoblast Share Price Up on FDA ‘Fast Track’ Designation (ASX:MSB)
At time of writing the Mesoblast Ltd [ASX:MSB] share price is up 7.26%. Soaring on the back of some exciting news. Their remestemcel-L treatment has secured ‘fast track’ status from the US Food & Drug Administration (FDA)...
Mesoblast Share Price Up on Novartis Collaboration (ASX:MSB)
At time of writing, the share price of Mesoblast Ltd [ASX:MSB] is up more than 14%, to trade at $3.73. We take a look at the details of Mesoblast’s latest announcement to work with pharma giant on remestemcel-L commercialisation